Latest Clinical trial Stories
At Six Months Post Launch, Almost One Third of Surveyed Urologists have Prescribed Xtandi in Clinical Practice, According to a New Report from BioTrends Research Group EXTON, Pa., May 6, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists and medical oncologists prescribed...
BUFFALO, N.Y., May 6, 2013 /PRNewswire/ -- Kinex Pharmaceuticals and Zenith Technology Corporation, through its affiliate ZenRx, announced today the execution of a collaborative licensing agreement granting Zenith Technology commercial rights to Oraxol and Oratecan in New Zealand and Australia. ZenRx will provide an upfront payment, milestones and royalties. Importantly, Zenith Technology Corporation will commit a significant amount of resources to the Oraxol and Oratecan global...
AG Mednet Brings Quality Assurance and Compliance Automation to Multi-Center, Multi-National Cardiovascular Clinical Trials BOSTON, May 6, 2013 /PRNewswire/ -- AG Mednet today announced a new core lab partnership with the Methodist DeBakey Heart & Vascular Center (MDHVC) echocardiography core laboratory at The Methodist Hospital in Houston. By selecting AG Mednet quality assurance and compliance software, MDHVC is strengthening its commitment to quality in multi-center and...
EyeKor, LLC, a new service provider dedicated to the support of ocular clinical trials, announces FDA 510k clearance of its EXCELSIOR™ image management software as a class 2 medical device, with indications for use specifically for managing ophthalmic clinical trial data. DAVIS, CA and MADISON, WI (PRWEB) May 03, 2013 EyeKor, LLC, a new service provider dedicated to the support of ocular clinical trials, announces FDA 510k clearance of its EXCELSIOR™ image management software as a...
BOSTON, May 3, 2013 /PRNewswire/ -- Bio-Optronics, Inc. and Schulman Associates IRB are proud to announce their partnership and their newly integrated regulatory compliance module for the Clinical Conductor Enterprise CTMS application. This collaboration offers Clinical Conductor Enterprise CTMS users streamlined IRB interactions from one centralized location. The new module will be officially unveiled during the MAGI East Clinical Research Conference in Boston, MA on May 5(th). "One...
REDWOOD CITY, Calif., May 3, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first quarter 2013 financial results after market close on Wednesday, May 8, 2013. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific...
Fast-growing CRO Enhances Ability to Offer Sponsors Cost-Effective EDC Platform. Sunnyvale, California, and Piscataway, New Jersey (PRWEB) May 02, 2013 Clinovo, Inc., a technology and services company headquartered in the Bay Area, focused on global solutions for the clinical trials industry, today announced that it has signed Global PharmaTek LLC to its ClinCapture® CRO Partner Program. Clinovo’s ClinCapture® CRO Partner Program is a non-exclusive enterprise agreement and...
- Conference call scheduled today at 4:30 p.m. Eastern time - SEATTLE, May 2, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2013. "In the first quarter, we generated initial commercial sales of PIXUVRI(®) in countries in the European Union where there is market access pending the completion of the reimbursement process," said James Bianco, M.D., President and CEO of CTI. "Although...
Conference call to be held on Thursday, May 2 at 4:30pm Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, May 2, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter 2013 financial results. OGX-427 Program Update In January 2013, the Company initiated the ORCA(TM) (Ongoing Studies Evaluating Treatment Resistance...
Cats with renal disease also may have "silent killer" RALEIGH, N.C., May 2, 2013 /PRNewswire/ -- The largest known veterinary clinical trial of its kind with 35 study sites in the United States and Canada is currently evaluating cats with kidney disease to determine if they also have hypertension (high blood pressure). Kidney disease and hypertension often occur together, especially in older cats. Hypertension has been called a "silent killer" and is difficult to diagnose because...
